Semler Scientific Inc (SMLR) was Resumed by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $8. Rodman & Renshaw advised their investors in a research report released on Apr 15, 2016.
In a different news, on Nov 4, 2015, Aidan Matthew Collins (director) purchased 1,000 shares at $3.38 per share price.
Semler Scientific Inc. is a medical risk assessment company. The Company develops manufactures and markets products that assist healthcare providers in monitoring patients and evaluating chronic diseases. The Company markets and licenses FloChec which is a United States Food and Drug Administration (FDA) cleared product. FloChec is a four-minute in-office blood flow test. FloChec is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a tool for internists and primary care physicians to conduct blood flow measurements. It offers FloChec product to cardiologists internists nephrologists endocrinologists podiatrists and family practitioners. The Company’s FloChec features a sensor clamp that is placed on the toe or finger much like pulse oximetry devices. The Company provides FloChec product and services through salespersons and through its distributor.